


To the Chairman of the Scientific Jury,

Constituted by Order

N P2015/13.07.2023

of the Rector of MU-Plovdiv

Scientific Review



For the promotion to the academic position "Associated Professor", in the scientific specialty "Pediatrics", at the Department of Pediatrics and Medical Genetics "Prof. Dr. Ivan Andreev" of MU-Plovdiv, announced in State Gazette, issue no. 32/08/04/2023

Prepared by: Assoc. Prof. Dr. Boryana Emanuilova Avramova, PhD,

Department of Pediatrics of the Medical University - Sofia

The current promotion procedure is for two part-time academic positions "Associated Professor" in the scientific specialty "Pediatrics" at the Department of Pediatrics and Medical Genetics of MU-Plovdiv, and two candidates participate. This statement is for Dr. Hasan Aliev Burnusuzov, PhD.

Description of the submitted materials for the competition:

The submitted materials for participation in the competition are complete, clearly arranged and comply with the requirements of the Law for the Academic Development in Bulgaria and the regulations for its application at MU-Plovdiv. They include: application form to the Rector for participation in the competition; CV; notarized copies of diplomas; certificates of teaching activity and study load; list of publications in specialized scientific journals; reports on impact - factor; journal publications, referenced and indexed in global databases; lists and copies of other scientific works and publications; of published educational materials; of participation in scientific forums; evidence of participation in scientific projects; a list of citations from NACID and Central Library; author reference - self-assessment for scientometric indicators; statement of originality; certificates and other documents.

Biographical data:

Dr. Hasan Aliev Burnusuzov was born on August 30, 1982. In 2001, he graduated from the English high school in Plovdiv, and in 2007 from the Medical University in Plovdiv, with MD in medicine. In 2014, he acquired a specialty in Pediatrics and in 2022 in Clinical Immunology. In 2013, after a successfully defended dissertation, he obtained the educational and scientific degree "Doctor in Medicine/ PhD".

Dr. Burnusuzov's professional and academic development includes: 2007-2008 - doctor at the Cytomedika AGPPMP - Plovdiv; 2008 - 2010 doctor - resident in the outpatient clinic of the "Vela" medical center - Plovdiv; from 2010 until now consecutively doctor - specialist pediatrician and clinical

immunologist, Chief Administrative Assistant in the Clinic of Pediatrics - Oncohematological Unit and in the Laboratory of Clinical Immunology of the Faculty of Medicine in MU-Plovdiv.

In 2013, he successfully defended a dissertation on the topic: "Flow cytometric monitoring of minimal residual disease in children with acute lymphoblastic leukemia".

Scientific Publications (articles): 36 total:

Dissertation and abstract - 1 each.

Scientific monographs, textbooks, study aids, compendiums, and manuals – 3, including a monograph from 2023 with a volume of 238 pages, which meets the requirements for a habilitation thesis.

Articles – 15 pcs. in Bulgarian journals, of which 10 are referenced in international databases, and 5 in international journals, of which 4 are referenced in international databases and with an impact factor.

Scientific communications – 3 published as full-text abstracts in journals referenced in international databases, 1 in a journal with an impact factor.

Participation in scientific projects:

He is a participant in 10 projects financed by the MU - Plovdiv and Sofia, in one of them he participates in the management of the project.

Teaching activity: conducts lectures, exercises, participation in examinations of students of medicine and dentistry, and trainee doctors in Bulgarian and English, and training in a simulation center - for the period from 2019 to 2022 (3 academic years in total) has 2742 hours.

Scientific indicators:

1. IF - referenced and indexed editions Scopus/WOS - 17.32

2. Citations (IC) - in scientific publications, referenced and indexed in world-famous databases with scientific information - 24; in monographs and collective works – 1, and in non-refereed journals with scientific review – 1; total impact - citation factor - 151,031; h-index-3.

Dr. Burnusuzov has extensive clinical experience in the field of pediatrics, pediatric oncohematology and clinical immunology. He was a reviewer of 5 articles. Participates in the international scientific network for the study of flow cytometric determination of MRD in children with acute leukemia, in the I-BFM ALL FLOW MRD-SG, led by Assoc. Prof. Dr. M. Dvorak from St. Anna CCRI- Vienna, Austria

The scientific developments of Dr. Burnusuzov in the period 2009-2023. are in several areas of pediatrics, mainly pediatric oncohematology and clinical immunology:

A. Contributions of original character

1. For the first time in Bulgaria, a systematic prospective study of MRD in children with acute lymphoblastic leukemia (ALL) was conducted, using a modern, highly sensitive 8-color multiparameter flow cytometric (MP FCM) methodology (R#9).

2. For the first time in our country, the 8-color MP FCM has been standardized and approved methodology for monitoring MRD in children with ALL. It has sufficient informativeness and reliability to be used as a routine stratification criterion in children with acute lymphoblastic leukemia (R#9, R#13.13).

3. The criteria determining the quality of the results of the 8-color MP FCM methodology have been specified, which contributes to unifying the credibility of laboratory results with those of international standardized laboratories. Until now, as the main operator of children's ALL samples, in the flow cytometry laboratory at the Department of Medical Microbiology and Immunology, resp. The laboratory of clinical immunology of UMBAL "St. Georgi" Plovdiv, Dr. Burnusuzov successfully participated in all annual external evaluations of the quality of the research within the international scientific group for the study of MRD by flow cytometry - I-BFM ALL FLOW MRD SG network (R№13.4). The recognition for this is the successful completion of training (R#32.4.2.1.1 and 32.4.2.1.2) and twining-program and obtaining "graduation" for B-ALL, (R# 32.2.3).

4. Prerequisites have been created for routine determination of MRD in children with ALL through MP FCM as a condition for the introduction of modern, risk-adapted therapeutic protocols. Thanks to this, the center has been shaped as reference national center for MRD research in children's ALL, a Bulgaria is included in the international protocols for the treatment of children with ALL -ALL IC BFM 2009, ALL IC BFM 2022 and ALL IC REL 22.

5. For the first time in Bulgaria, as part of the pediatric oncohematology team, described the use of anti-GD2 immunotherapy in patients with metastatic, GD2-positive Ewing sarcoma (ES) or Ewing-like sarcoma. The experience of 3 cases treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapy regimens is reported. (R#13.2).

B. Scientific and applied contributions

1. The correlation between persistent MRD, established by MP FCM, and other prognostic markers (clinical and laboratory) during induction treatment, as well as the interrelationships between MRD levels, and clarified the dynamics of the blast population during the course of treatment, as well as the role of therapeutic immunophenotypic modulation as a complicating factor for the analysis (R#9, R#13.13).

2. The new possibilities for increasing the sensitivity and the specificity of the MP FCM, thanks to the winning PERIMED project and the purchased modern equipment, as well as the UP, together with colleagues from the Department of Medical Microbiology and Immunology, a 14-color methodology for the study of MRD in DALL has been developed and is currently being implemented, and the quality of the research is significantly improved (R№14.1, R№ 14.16).

3. Thanks to a won VUP with a team from the Department of Medical biology, the clinical significance of anti-L-asparaginase antibodies was analyzed in relation to relapse-free survival of children with ALL, enabling implementation in the practice of their routine research (R#14.4).

4. On the basis of earned UP and jointly with the oncology clinic, the role of antineuronal antibodies in patients with paraneoplastic syndrome is being studied (PN№20.).

5. The other main direction in the scientific work of Dr. Burnusuzov is represented by the study of primary immune deficiencies, with special attention being paid to the screening of infants with

acquired CMV-infection (RN# 13.5) or "signal" pneumocystis pneumonia (R#13.10, 14.5), as well as the diagnosis and the treatment of disorders in the oxidative burst or innate immunity (RN#14.6, 14.10). Some of these issues (screening, diagnosis and treatment), especially in patients with disorders of humoral immunity, are also discussed in detail in the monograph (R#10).

C. Contributions of a scientific and confirmatory nature

1. The role of targeted therapy and immunotherapy in the treatment of malignant diseases, as well as in pediatric rheumatology, as modern, highly effective, even in malignant tumors resistant to classical therapy, with fewer side effects and well tolerated was reviewed. (R#14.7; 14.11; 14.15).

2. The new immunological aspects in etiopathogenesis are discussed in detail, the diagnosis and therapy of some rare but significant diseases, such as Crohn's disease, immune thrombocytopenia, Langerhans histiocytosis, and the leading directions in the development of scientific research in this rapidly developing field of knowledge and practice are outlined (RN#13.3, 13.6, 14.18).

3. Special attention is paid to palliative care for children with oncohematological diseases, as well as moral and ethical problems at the end of life, as a number of issues of anesthesia, supportive care, but also issues such as euthanasia and the resuscitation status of the patient are delineated (R#13.12 and 14.8).

4. The modern recommendations for vaccination of children receiving immunosuppressive therapy have been confirmed (R# 14.3). To the same questions, but concerning patients with humoral immune deficiencies, a whole chapter of the monograph is dedicated, where the recommendations for individual PIDs are discussed in detail (P#10).

5. Casuistic cases of scientific interest are also described and the therapeutic difficulties, not only for specialists, but also for general practitioners, students and trainees, due to the challenges they pose to the doctor who encountered them (R#13.14, 14.2, 14.17, 14.18).

D. Contributions of a theoretical nature

1. Through the conducted fundamental scientific research on cellular metabolism, the role of Atovaquone on pALL cells in vitro was demonstrated, finding a significant reduction in basal respiration and ATP levels, reduced proliferation, cell cycle arrest and induction of apoptosis (R#13.7).

Scientometric indicators for occupying the academic position "Associated Professor", presented by Dr. Burnusuzov:

1. Scientific production meeting the minimum scientometric requirements - total number of points 287.24 with a mandatory minimum of 200 points.

2. Citations reflecting the candidate's scientific activity - total number of points 420.

3. Full-text publications in scientific journals and collections, beyond the minimum scientometric requirements - total number of points 198.7.

Overall assessment of Dr. Burnusuzov's compliance with the mandatory conditions:

After analyzing the submitted evidentiary material for the competition, I can conclude that Dr. Burnusuzov meets the mandatory scientometric indicators according to the regulation for occupying the academic position of "Associated Professor". I believe that the scientific and applied value of Dr. Burnusuzov's work and his modern approach characterize him as an excellent pediatrician and specialist in pediatric hematology, oncology and immunology, able to work in a team, with in-depth knowledge and experience in the main areas of pediatrics and a teacher with a lot of experience. His academic load, scientometric indicators, as well as his ability to pass on his knowledge to young colleagues, fully meet the requirements of the Law for Academic Development of the Republic of Bulgaria and the rules for its application at MU-Plovdiv for awarding the academic position "Associated Professor".

Conclusion: I recommend the members of the esteemed Scientific Jury to award Dr. Hasan Aliev Burnusuzov, MD, the academic position of "Associated Professor".

Assoc. Dr. Boryana Avramova, dm



Заличено на основание
Чл.5 §1, 6. "В" Регламент (ЕС)2016/679